RA'ANANA, Israel, Dec. 28,
2023 /PRNewswire/ -- Inspira Technologies
OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW)
(the "Company" or "Inspira"), a pioneer in life support
technology with a vision to supersede traditional mechanical
ventilators, today announces the closing of its previously
announced registered direct offering of 3,031,250 ordinary shares
(or ordinary share equivalents in lieu thereof), at a purchase
price of $1.28 per ordinary share (or ordinary share
equivalents in lieu thereof). Inspira has also issued in a private
placement warrants to purchase up to an aggregate of 3,031,250
ordinary shares at an exercise price of $1.28 per share.
The warrants are exercisable immediately upon issuance on the
closing date and will expire on the date that is three and one-half
half year after the closing date. The aggregate gross
proceeds from the offering were approximately $3.88 million, before deducting placement agent
fees and other estimated offering expenses.
H.C. Wainwright & Co. acted as the exclusive placement
agent for the offering.
The securities described above (excluding the unregistered
warrants and the ordinary shares underlying the unregistered
warrants) were offered and sold by the Company in a registered
direct offering pursuant to a "shelf" registration statement on
Form F-3 (Registration No. 333-266748), including a base
prospectus, previously filed with the Securities and Exchange
Commission (SEC) on August 10, 2022
and declared effective by the SEC on August
18, 2022. The offering of such securities in the registered
direct offering were made only by means of a prospectus supplement
that forms a part of the registration statement. A final prospectus
supplement and an accompanying base prospectus relating to the
registered direct offering was filed with the SEC and is available
on the SEC's website located at http://www.sec.gov. Electronic
copies of the final prospectus supplement and accompanying base
prospectus may also be obtained, by contacting H.C. Wainwright
& Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711
or e-mail at placements@hcwco.com.
The unregistered warrants described above were offered in
a private placement under Section 4(a)(2) of the Securities Act of
1933, as amended (the "Act"), and Regulation D promulgated
thereunder and, along with the ordinary shares underlying such
warrants, have not been registered under the Act, or applicable
state securities laws. Accordingly, the warrants and the underlying
ordinary shares may not be reoffered or resold in the United
States except pursuant to an effective registration statement
or an applicable exemption from the registration requirements of
the Act and such applicable state securities laws.
This press release shall not constitute an offer to sell
or a solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or jurisdiction.
About Inspira Technologies OXY BHN Ltd.
Inspira Technologies is leading the way in transforming
life-support care. Its innovative solutions are paving the way for
direct blood oxygenation, bypassing the lungs, and potentially
reducing the need for traditional mechanical ventilation. Beyond
this, the Company is committed to advancing blood circulation
technology and incorporating AI-driven monitoring systems. These
advancements are part of its strategy to offer more
patient-focused, data-informed care. The integration of these
technologies signifies the potential to enhance patient outcomes
and streamline hospital operations, marking a new era in
respiratory care.
For more information, please visit our corporate
website:
https://inspira-technologies.com/
Forward-Looking Statement Disclaimer
This press release contains express or implied
forward-looking statements under US Federal securities laws. These
forward-looking statements and their implications are based only on
the current expectations of the management of the Company. They are
subject to several factors and uncertainties that could cause
results to differ materially from those described in the
forward-looking statements. Except as otherwise required by law,
the Company undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's annual report on Form 20-F for the
fiscal year ended December 31, 2022,
filed with the SEC, which is available on the SEC's website,
www.sec.gov.
For more details:
Public Relations Manager
Adi Shmueli
Inspira
Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2023 Inspira Technologies OXY B.H.N.
LTD., All rights reserved.
MRK-ARS-081
Logo -
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-technologies-closes-on-3-88-million-registered-direct-offering-302023462.html
SOURCE Inspira Technologies